利用死后毒理学检测项目检出的赛拉嗪相关死亡的特征:定性与定量分析
该研究评估了密歇根州死后毒理学检测项目中赛拉嗪阳性病例的趋势、死者特征、药物共检出及血药浓度。2019年10月至2023年6月共279例赛拉嗪阳性死亡,全部检出芬太尼;赛拉嗪阳性样本中仅30%检出纳洛酮,而赛拉嗪阴性且阿片阳性的样本中21.2%检出纳洛酮。赛拉嗪阳性死亡占比从2021年的3.2%升至2023年1–6月的4.7%。55份死者血样赛拉嗪浓度为5.2–200 µg/L,中位共检出5类药物组。作者认为纳洛酮检出率相对较低,凸显增加纳洛酮可及性与分发的重要性。
要点
- 2019年10月至2023年6月密歇根州共279例死后赛拉嗪阳性死亡,其中100%检出芬太尼。
- 赛拉嗪阳性死亡占比从2021年的3.2%上升至2023年1–6月的4.7%。
- 赛拉嗪阳性样本中仅30%检出纳洛酮,赛拉嗪阴性且阿片阳性的样本中21.2%检出纳洛酮。
- 赛拉嗪阳性死亡中位共检出5类药物组,55份死者血样赛拉嗪浓度为5.2–200 µg/L。
- 作者认为纳洛酮检出率相对较低,凸显继续增加纳洛酮可及性与分发的重要性。
适用人群与场景
- 密歇根州死后毒理学检测项目中赛拉嗪阳性的死亡病例,时间为2019年10月至2023年6月。
诊断标准与关键阈值
- 死后血液样本中赛拉嗪阳性定义为赛拉嗪阳性死亡病例。
研究设计与关键结果
- 研究类型为死后毒理学检测项目分析,共纳入279例赛拉嗪阳性死亡,时间范围为2019年10月至2023年6月。
- 279例赛拉嗪阳性死亡中100%检出芬太尼。
- 赛拉嗪阳性样本中30%检出纳洛酮,赛拉嗪阴性且阿片阳性的样本中21.2%检出纳洛酮。
- 赛拉嗪阳性死亡占比从2021年的3.2%上升至2023年1–6月的4.7%。
- 赛拉嗪阳性死亡中位共检出5类药物组。
- 55份死者血样死后赛拉嗪浓度为5.2–200 µg/L。
证据类型、等级与局限
- 证据类型为死后毒理学检测项目分析。
- 局限:原文指出有限的人类赛拉嗪临床研究妨碍了对这些数据进行准确解读和因果归因。
对床旁实践的改变
- 作者认为纳洛酮检出率相对较低,凸显继续增加纳洛酮可及性与分发的重要性。
- 作者指出赛拉嗪相关死亡常涉及多种其他药物。
- 作者认为进一步的临床和毒理学研究有助于将赛拉嗪在阿片过量中的临床意义置于背景中理解、澄清流行病学和临床研究,并为适当的公共卫生信息提供依据。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
INTRODUCTION: The United States drug overdose crisis continues to evolve. Xylazine has been increasingly identified as an adulterant in illicit opioid supplies. The incorporation of novel adulterants, like xylazine, into the illicit drug supply adds complexity to post-mortem toxicology testing, public health messaging, substance use mitigation, and the treatment of people who use drugs.
METHODS: We assessed trends, decedent characteristics, drug co-detection, and blood concentrations of xylazine-positive post-mortem cases in Michigan. We utilized a toxicology testing program capable of detecting several opioids and non-opioids in post-mortem blood samples within 72 hours.
RESULTS: A total of 279 deaths were xylazine-positive between October 2019 and June 2023, with 100 percent positive for fentanyl. Only 30 percent of xylazine-involved samples were positive for naloxone, while 21.2 percent of xylazine-negative and opioid-positive samples were positive for naloxone. The percentage of xylazine-positive deaths increased from 3.2 percent in 2021 to 4.7 percent in January-June 2023. A median of five total drug groups were present among xylazine-positive deaths. Post-mortem xylazine concentrations for 55 decedent blood samples ranged from 5.2 to 200 µg/L.
DISCUSSION: Our study demonstrated increases in xylazine detection among post-mortem cases. Our findings are consistent with national trends of increasing xylazine presence among drug-involved deaths. Our range of detected post-mortem xylazine blood concentrations was consistent with what has been reported in previous literature. Fentanyl was detected in 100 percent of xylazine-positive overdose deaths. Naloxone detection was relatively low, highlighting the continued importance of increasing naloxone access and distribution. Deaths associated with xylazine often involved multiple other drugs. Limited human clinical xylazine research precludes accurate interpretation and attribution of causality from these data.
CONCLUSIONS: Overdose-related deaths with xylazine detection are increasing in Michigan and across the United States. Further clinical and toxicological research can help contextualize the clinical significance of xylazine in opioid overdose, clarify epidemiologic and clinical research, and inform appropriate public health messaging.
参考来源
- Vohra V, Stroh-Steiner GK, Jones P, et al. Qualitative and quantitative characteristics of xylazine-associated deaths detected using a post-mortem toxicology testing program. Clin Toxicol (Phila). 2024. PMID: 38088581. doi:10.1080/15563650.2023.2288540
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。